Family medicine clinicians initiating or managing GLP-1 therapy frequently encounter patients with prediabetes, and this clustering data reinforces that not all prediabetes carries equivalent metabolic risk or treatment response. Patients with the severe insulin resistance and obesity phenotype identified in this analysis overlap substantially with the population most likely to be candidates for GLP-1 receptor agonists, meaning these individuals may benefit from combination or sequential metabolic therapy rather than a single-agent approach. Phenotypic stratification at the point of prediabetes diagnosis can therefore directly inform decisions about when to escalate from metformin alone to GLP-1 therapy or to consider both concurrently.
A secondary clustering analysis of the Diabetes Prevention Program (DPP) identified two biologically distinct prediabetes phenotypes within the trial population. One cluster was characterized by severe insulin resistance, higher BMI, and younger age, while the other presented with milder metabolic dysregulation and relatively preserved insulin sensitivity. This phenotypic stratification revealed that the overall modest benefit of metformin observed across the full DPP cohort was not uniformly distributed, but instead concentrated almost entirely within the insulin-resistant, high-BMI subgroup.
Among patients in the severe insulin resistance and obesity cluster, metformin demonstrated a substantially greater reduction in progression to type 2 diabetes compared to the trial-level aggregate effect. The benefit in the more metabolically preserved cluster was minimal and, in some analyses, negligible. These findings align mechanistically with metformin’s primary mechanism of action, which centers on hepatic glucose production suppression and insulin sensitization, effects that would be expected to yield greater clinical impact in patients where those pathways are most dysregulated.
For prescribers managing prediabetes, this analysis supports a more individualized approach to metformin initiation. Patients presenting with features of severe insulin resistance, elevated BMI, and younger age represent the population most likely to derive meaningful benefit from pharmacologic intervention with metformin. Conversely, patients with milder prediabetes phenotypes and preserved insulin sensitivity may not experience comparable risk reduction, which has practical implications for how clinicians prioritize metformin versus intensive lifestyle intervention across heterogeneous prediabetes populations.
Clustering analysis of patients with prediabetes identified two distinct metabolic phenotypes, with metformin’s preventive benefit concentrated specifically in those characterized by severe insulin resistance and obesity rather than in the broader prediabetes population. This finding reinforces that prediabetes is not a single uniform condition, and applying metformin broadly to all patients with elevated fasting glucose or HbA1c may not be clinically appropriate. Family medicine providers should consider phenotyping prediabetic patients by degree of insulin resistance and body composition before initiating metformin for diabetes prevention. In practice, tools such as fasting insulin levels or HOMA-IR scoring can help identify which patients in your panel are most likely to benefit, making for more targeted and evidence-based conversations during shared decision-making visits.
“The real clinical takeaway here is that prediabetes is not a monolithic diagnosis, and treating it as one leads us to underprescribe in the patients who stand to benefit most. This clustering data reinforces what I see in practice: the patient with severe insulin resistance and significant adiposity is a fundamentally different metabolic animal than someone with mild glucose elevation and preserved insulin sensitivity. When I am sitting across from a patient with a BMI over 35 and fasting insulin levels that are through the roof, this evidence gives me greater confidence to reach for metformin as an early, proactive tool rather than defaulting to watchful waiting. The practical implication is that we need to be phenotyping our prediabetic patients more rigorously at the point of care, because a blanket lifestyle counseling approach may be adequate for one subgroup while representing a missed therapeutic window for another.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is prediabetes and why does it matter for GLP-1 therapy?
Prediabetes is a condition where blood sugar levels are higher than normal but not yet high enough to be diagnosed as type 2 diabetes. It represents a critical window for intervention, and GLP-1 receptor agonists have shown meaningful effects on blood sugar regulation and weight during this stage. Treating prediabetes early may reduce the likelihood of progressing to full diabetes.
How does GLP-1 therapy compare to metformin for preventing diabetes in high-risk patients?
GLP-1 receptor agonists and metformin work through different mechanisms, and they are not directly interchangeable for diabetes prevention. Metformin has the longest track record in diabetes prevention research, but GLP-1 therapies offer additional benefits including significant weight loss and improved insulin sensitivity. Your physician can help determine which approach is most appropriate based on your specific metabolic profile.
What is insulin resistance and how does it relate to my eligibility for GLP-1 therapy?
Insulin resistance means your body’s cells do not respond efficiently to insulin, which forces the pancreas to produce more insulin to manage blood sugar. Patients with severe insulin resistance and obesity represent a subgroup that may benefit most from targeted metabolic therapies. GLP-1 receptor agonists can improve insulin sensitivity as part of their broader metabolic effects.
Does obesity affect how well GLP-1 therapy works for diabetes prevention?
Research consistently shows that patients with obesity and insulin resistance respond more robustly to metabolic interventions. GLP-1 receptor agonists produce meaningful weight loss in many patients, which directly improves insulin sensitivity and lowers diabetes risk. The degree of benefit can vary based on individual metabolic characteristics identified through clinical evaluation.
Are all prediabetes patients the same when it comes to choosing a treatment?
No, research has identified distinct prediabetes phenotypes that differ in their underlying metabolic drivers and their responses to specific therapies. Some patients have predominant insulin resistance while others may have impaired insulin secretion as their primary issue. Understanding your phenotype helps your physician select the most effective treatment strategy.
Can GLP-1 therapy actually prevent me from developing type 2 diabetes?
Clinical evidence suggests that GLP-1 receptor agonists can reduce blood sugar levels, promote weight loss, and improve several metabolic markers associated with diabetes risk. Whether this translates to formal diabetes prevention is an active area of research, and results depend on individual patient factors. Consistent use combined with lifestyle changes offers the strongest overall approach.
Should I be taking both metformin and a GLP-1 medication at the same time?
Combination therapy with metformin and a GLP-1 receptor agonist is used in clinical practice and can offer complementary metabolic benefits. Metformin primarily reduces liver glucose production while GLP-1 therapies work through insulin secretion, glucagon suppression, and weight reduction. Your physician will assess your full metabolic picture before recommending a combination approach.
How does my weight affect whether I should consider GLP-1 therapy for blood sugar management?
Excess body weight, particularly when associated with insulin resistance, is a strong driver of progression from prediabetes to type 2 diabetes. GLP-1 receptor agonists address both metabolic and weight-related components simultaneously, making them particularly relevant for patients with obesity. Weight loss achieved through GLP-1 therapy can independently improve blood sugar control.
What kind of testing helps determine if I am the right candidate for GLP-1 therapy?
Relevant tests include fasting glucose, hemoglobin A1c, fasting insulin levels, and sometimes a glucose tolerance test to characterize your metabolic pattern. These results help identify whether insulin resistance or insulin secretion impairment is the dominant issue in your prediabetes. This information allows your physician to match therapy to your individual phenotype more precisely.
If I am already on metformin for prediabetes, is there any reason to discuss GLP-1 therapy with my doctor?
Yes, particularly if you have not achieved adequate blood sugar control, have significant obesity, or continue to progress toward diabetes despite metformin use. GLP-1 receptor agonists offer additional mechanisms of action that metformin does not address, including appetite regulation and direct effects on pancreatic function. A reassessment of your current therapy plan is a reasonable conversation to have with your physician.
